By Mariam Sunny and Kunal Das March 30 (Reuters) - The U.S. Food and Drug Administration has approved a higher dose of Biogen ...

March 30 (Reuters) - The U.S. Food and Drug Administration has approved a higher-dose version of Biogen's drug for a rare ...

Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of t ...

The US Food and Drug Administration has approved a higher-dose version of Spinraza, a key therapy from Biogen Inc ...

In late March 2026, Biogen announced that the U.S. FDA approved a new High Dose Regimen of SPINRAZA (nusinersen) for spinal muscular atrophy, allowing faster loading with two 50 mg doses and 28 mg ...

After Spinraza's FDA approval nearly a decade ago, Biogen's spinal muscular atrophy (SMA) drug captured rapid momentum and delivered blockbuster-level sales in just its second year on the market. | ...

William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s ...

Biogen Inc. closed 7.33% below its 52-week high of $202.41, which the company reached on February 6th.

After a surprise rejection in September last year, the FDA has signed off on a high-dose formulation of Biogen’s spinal muscular atrophy drug Spinraza. The approval, announced Monday, will allow a ...

After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus ...

US biotech Biogen has announced positive results from the Phase II part of the AMETHYST Phase II/III study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE).